Health Care & Life Sciences » Pharmaceuticals » Biotechnology industry | Top pharma and biotech launches 2018 by 2022 revenue forecast

Projection of top 2018 pharma and biotech launches by revenue 2022

Top biotech and pharma product launches in 2018 and revenue forecast for 2022 (Figures expressed in millions of U.S. dollars, unless otherwise specified)

The data illustrates the top biotech and conventional pharmaceutical product launches globally in 2018 and their projected revenues for 2022. AbbVie's probably in 2018 to be-launched product Elagolix is expected to garner some 1.2 billion USD in 2022.

Bictegravir/F/TAF (Gilead) 5.05
Semaglutide (Novo Nordisk) 2.72
Epacadostat (Incyte) 1.94
Rova-T (AbbVie) 1.44
Ozanimod (Celgene) 1.27
Apalutamide (Johnson & Johnson) 1.24
Elagolix (AbbVie) 1.21
AVXS-101 (Avexis) 1.14
Lanadelumab (Shire) 1.12
Epidiolex (GW Pharma) 0.96

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.